Betamethasone + Salicylic acid


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Topical Hyperkeratotic and scaling skin conditions; Corticosteroid-responsive dermatoses; Inflammatory skin conditions As soln/oint: Apply to the affected area 1-2 times daily for 2 wk. Max: 60 g/wk.
Dosage Details
Topical/Cutaneous
Corticosteroid-responsive dermatoses, Hyperkeratotic and scaling skin conditions, Inflammatory skin conditions
Adult: As soln (containing betamethasone dipropionate 0.05% w/w and salicylic acid 2% w/w) or oint (containing betamethasone dipropionate 0.05% w/w and salicylic acid 3% w/w or betamethasone valerate 0.1% w/w and salicylic acid 3% w/w): Apply to the affected area 1-2 times daily for 2 wk. Max: 60 g wkly.
Child: Max duration: 5 days.
Contraindications
Viral skin infections (e.g. vaccinia, varicella and herpes simplex), TB, acne, rosacea, napkin eruptions, fungal or bacterial skin infections w/o suitable concomitant anti-infective therapy, perioral dermatitis, ulcerative conditions, perianal and genital pruritus.
Special Precautions
Absorption of corticosteroid through the skin is increased when used w/ occlusive dressings. Avoid long term continuous therapy. Childn. Pregnancy and lactation.
Adverse Reactions
Irritation, burning, itching, dryness, folliculitis, maceration of skin, skin atrophy, hypertrichosis, acneiform eruptions, secondary infection, hypopigmentation, perioral dermatitis, allergic contact dermatitis, striae and miliaria.
Patient Counseling Information
Avoid contact w/ the eyes and mucous membranes.
Overdosage
Symptoms: Pituitary-adrenal suppression resulting in secondary adrenal insufficiency and produce manifestations of hypercorticism, including Cushing's disease. Salicyclism symptoms. Management: Symptomatic and supportive treatment. Treat electrolyte imbalance. Slow withdrawal in case of chronic toxicity. Admin oral Na bicarbonate to alkalinise the urine and force diuresis.
Action
Description: Betamethasone is a synthetic fluorinated corticosteroid. It is active topically and produces a rapid and sustained response in inflammatory dermatoses. Salicylic acid has keratolytic action. It softens keratin, loosens cornified epithelium and desquamates the epidermis. It aids in the penetration of betamethasone.
Pharmacokinetics:
Absorption: Betamethasone: Percutaneous absorption depends on several factors e.g. use of occlusive dressings and integrity of the epidermal barrier. Salicylic acid: Exerts only local action after topical application.
Distribution: Betamethasone: Rapidly distributed to all body tissues. Crosses the placenta; enters breast milk (small amounts). Plasma protein binding: Extensive (mainly to globulin).
Metabolism: Betamethasone: Metabolised mainly in the liver.
Excretion: Betamethasone: Via urine; may also be excreted via the bile.
Chemical Structure

Chemical Structure Image
Betamethasone

Source: National Center for Biotechnology Information. PubChem Database. Betamethasone, CID=9782, https://pubchem.ncbi.nlm.nih.gov/compound/Betamethasone (accessed on Jan. 21, 2020)


Chemical Structure Image
Salicylic acid

Source: National Center for Biotechnology Information. PubChem Database. Salicylic acid, CID=338, https://pubchem.ncbi.nlm.nih.gov/compound/Salicylic-acid (accessed on Jan. 21, 2020)

Storage
Store at or below 25°C.
References
Betosalic Ointment (T.O. Chemicals). MIMS Thailand. http://www.mims.com/thailand. Accessed 07/08/2015.

Buckingham R (ed). Pharmacokinetics of Corticosteroids. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Betamethasone, Betamethasone Benzoate, Betamethasone Dipropionate, Betamethasone Valerate (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 07/08/2015.

Disclaimer: This information is independently developed by MIMS based on Betamethasone + Salicylic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Beprosalic
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in